[Targeted therapies and radiotherapy in colorectal cancer]

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy Research

Context:

• Intracellular signal pathways are increasingly recognized for their role in modulating tumor response to radiation therapy.
• Experimental studies show promise in combining targeted therapies with radiotherapy to improve outcomes.
• Clinical trials are actively exploring these combinations to reduce locoregional recurrence rates.

Purpose:

• To review the role of intracellular signal pathways in radiation response.
• To highlight the potential of combining targeted therapies with radiotherapy.
• To discuss current and future clinical applications, particularly in rectal cancer.

Summary:

• Intracellular signaling pathways significantly influence tumor radiosensitivity, although identified factors do not consistently predict response to targeted therapies.
• Concurrent radiotherapy with monoclonal antibodies like bevacizumab (anti-VEGF) shows promise in rectal cancer.
• Further trials are planned for cetuximab (anti-HER1) combinations, while other inhibitors are in preclinical stages.

Impact:

• This research supports the development of novel therapeutic strategies combining targeted agents with radiotherapy.
• Findings may lead to improved treatment efficacy and reduced recurrence in various cancers.
• The study provides a basis for future clinical trials and personalized treatment approaches in oncology.